PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,110.00
Bid: 12,086.00
Ask: 12,088.00
Change: -56.00 (-0.46%)
Spread: 2.00 (0.017%)
Open: 12,186.00
High: 12,198.00
Low: 12,068.00
Prev. Close: 12,166.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: StanChart, AstraZeneca lift FTSE 100 into green

Fri, 28th Jul 2023 08:52

(Alliance News) - Stock prices in London opened higher on Friday, boosted by a mostly strong set of company earnings, while investors weighed recent central bank decisions.

The FTSE 100 index opened up 21.41 points, 0.3%, at 7,714.17. The FTSE 250 was down 90.04 points, 0.5%, at 19,183.33, and the AIM All-Share was down 1.13 points, 0.2%, at 768.16.

The Cboe UK 100 was up 0.1%, the Cboe UK 250 was down 0.5% at 16,860.93, and the Cboe Small Companies was up 0.1% at 13,816.04.

In European equities on Friday, the CAC 40 in Paris was down 0.4%, while the DAX 40 in Frankfurt was down 0.1%. French equities failed to get a boost from a stronger-than-expected gross domestic product print, and returned some of their gains from Thursday.

The French economy saw a surprisingly robust performance in the second quarter of this year, growing by 0.5% from the first quarter, the statistics office announced.

The figure was well above the INSEE statistics office's own forecast of 0.1% growth for April to June and the expectations of analysts. It was also ahead of the 0.2% quarter growth seen in the first quarter.

Meanwhile, stocks in the FTSE 100 were outperforming their continental counterparts.

Standard Chartered was the top performer, up 5.4%.

The Asia-focused bank launched a new USD1 billion share buyback programme, as it reported a 20% rise in profit in the first half of 2023 and raised its guidance for the full year.

Pretax profit in the six months that ended June 30 was USD3.32 billion, up 20% from USD2.77 billion a year before. Operating income increased by 11% to USD9.13 billion from USD8.23 billion, and StanChart also benefitted from a reduced credit impairment of USD161 million, down from USD263 million a year before.

StanChart declared a 6 cents per share ordinary interim dividend, up 50% from a year before.

NatWest's interim results received a more muted reception, however, with its shares rising 0.3%.

Fresh from scandal, the bank touted its "robust balance sheet, with a high-quality deposit base, high levels of liquidity and a well-diversified loan book". In the first half of 2023, total income rose to GBP7.73 billion from GBP6.22 billion a year before, as net interest income came in at GBP5.73 billion from GBP4.33 billion. Operating pretax profit climbed to GBP3.59 billion from GBP2.62 billion. It declared an interim dividend of 5.5 pence and intends to begin a buyback of up to GBP500 million in the second half, in addition to the GBP1.3 billion buyback completed in the second quarter.

The results come amid the dramatic fallout in the row sparked by Nigel Farage over the closure of his Coutts bank account, which culminated in the resignation of NatWest CEO Alison Rose and the boss of Coutts, which is owned by the banking group.

"The bank is in extremely good shape in virtually all of its key metrics," noted interactive investor's Richard Hunter.

AstraZeneca rose 3.4% as it said pretax profit surged to GBP4.35 billion in the first half 2023, from just USD800 million a year before. Revenue rose edged up to USD22.30 billion from USD22.16 billion. The company reported significantly lower cost of sales, down 41% to USD3.87 billion from USD6.51 billion.

"Each of our non-Covid-19 therapy areas saw double-digit revenue growth, with eight medicines delivering more than USD1 billion of revenue in the first half, demonstrating the strength of our business," said CEO Pascal Soriot.

In the FTSE 250, Vanquis Banking plunged 25%.

The lender swung to a pretax loss of GBP14.5 million in the first half, from a profit of GBP46.9 million the year before. Total income slipped to GBP237.1 million from GBP240.3 million.

Sterling was quoted at USD1.2782 early Friday, down from USD1.2865 at the London equities close on Thursday. The euro traded at USD1.0963, lower than USD1.0996.

In Asia on Friday, the Nikkei 225 index in Tokyo closed down 0.4%, having fallen as low as 2.4%. The yen strengthened following a policy adjustment from Japan's central bank.

The Bank of Japan said it will allow "greater flexibility" in controlling bond yields, as it raised its full-year inflation forecast to 2.5% from its previous estimate of 1.8%.

It said it would continue to allow 10-year JGB yields to "fluctuate in the range of around plus and minus 0.5 percentage points from the target level, while it will conduct yield curve control with greater flexibility regarding the upper and lower bounds of the range as references, not as rigid limits," the central bank said in a statement. The bank also kept its short-term interest rate target unchanged at minus 0.1%.

Against the yen, the dollar was quoted at JPY139.10, down versus JPY141.07.

In China, the Shanghai Composite closed up 1.8%, while the Hang Seng index in Hong Kong was up 1.4%. The S&P/ASX 200 in Sydney closed down 0.7%.

In the US on Thursday, Wall Street ended lower, with the Dow Jones Industrial Average down 0.7%, the S&P 500 down 0.6% and the Nasdaq Composite down 0.6%.

Equities had earlier made a bright start after figures showed the US economy grew by more than expected in the second quarter of 2023, according to the first estimate from the US Bureau of Economic Analysis.

Quarter-on-quarter gross domestic product in the US increased 2.4% on an annualised basis in the second quarter of the year. In the first quarter, real GDP increased 2.0%, showing that the US economy has gathered some momentum.

Investors will have a keen eye on the US personal consumption expenditures reading at 1330 BST, which contains the latest core personal consumption expenditures deflator - the Federal Reserve's preferred metric of inflation.

Friday's economic calendar also has a German GDP reading at 0900 BST and an inflation reading from the eurozone's largest economy at 1300 BST.

By Elizabeth Winter, Alliance News senior markets reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.